NasdaqGS - Delayed Quote • USD
Innoviva, Inc. (INVA)
At close: April 24 at 4:00 PM EDT
After hours: April 24 at 4:20 PM EDT
Earnings Estimate
CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
---|---|---|---|---|
No. of Analysts | 1 | 1 | 1 | 1 |
Avg. Estimate | 0.17 | 0.22 | 0.81 | 0.98 |
Low Estimate | 0.17 | 0.22 | 0.81 | 0.98 |
High Estimate | 0.17 | 0.22 | 0.81 | 0.98 |
Year Ago EPS | 0.42 | 0.02 | 2.2 | 0.81 |
Revenue Estimate
CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
---|---|---|---|---|
No. of Analysts | 1 | 1 | 1 | 1 |
Avg. Estimate | 68M | 75.81M | 300.74M | 333.75M |
Low Estimate | 68M | 75.81M | 300.74M | 333.75M |
High Estimate | 68M | 75.81M | 300.74M | 333.75M |
Year Ago Sales | 61.46M | -- | 310.46M | 300.74M |
Sales Growth (year/est) | 10.60% | -- | -3.10% | 11.00% |
Earnings History
CURRENCY IN USD | 3/31/2023 | 6/30/2023 | 9/30/2023 | 12/31/2023 |
---|---|---|---|---|
EPS Est. | 0.23 | 0.26 | 0.27 | 0.23 |
EPS Actual | 0.42 | 0.02 | 0.98 | 0.76 |
Difference | 0.19 | -0.24 | 0.71 | 0.53 |
Surprise % | 82.60% | -92.30% | 263.00% | 230.40% |
EPS Trend
CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
---|---|---|---|---|
Current Estimate | 0.17 | 0.22 | 0.81 | 0.98 |
7 Days Ago | 0.17 | 0.22 | 0.81 | 0.98 |
30 Days Ago | 0.17 | 0.22 | 0.81 | 0.98 |
60 Days Ago | 0.18 | 0.22 | 0.82 | 1.02 |
90 Days Ago | 0.18 | 0.22 | 0.82 | 1.02 |
EPS Revisions
CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
---|---|---|---|---|
Up Last 7 Days | -- | -- | -- | -- |
Up Last 30 Days | -- | -- | -- | -- |
Down Last 7 Days | -- | -- | -- | -- |
Down Last 30 Days | -- | -- | -- | -- |
Growth Estimates
CURRENCY IN USD | INVA | Industry | Sector | S&P 500 |
---|---|---|---|---|
Current Qtr. | -59.50% | -- | -- | 1.50% |
Next Qtr. | 1,000.00% | -- | -- | 11.40% |
Current Year | -63.20% | -- | -- | 5.20% |
Next Year | 21.00% | -- | -- | 13.40% |
Next 5 Years (per annum) | 19.34% | -- | -- | 11.09% |
Past 5 Years (per annum) | -6.33% | -- | -- | -- |
Research Analysis
Upgrades & Downgrades
Reiterates | EF Hutton: Buy | 5/10/2023 |
Reiterates | EF Hutton: Buy | 4/20/2023 |
Maintains | Goldman Sachs: Neutral | 3/3/2023 |
Maintains | Morgan Stanley: Underweight | 3/3/2023 |
Reiterates | EF Hutton: Buy | 3/3/2023 |
Maintains | Morgan Stanley: Underweight | 1/24/2023 |
Related Tickers
TYRA Tyra Biosciences, Inc.
16.00
-2.32%
IMCR Immunocore Holdings plc
58.47
+2.02%
DYN Dyne Therapeutics, Inc.
24.98
-1.81%
PTCT PTC Therapeutics, Inc.
25.21
-0.79%
ITOS iTeos Therapeutics, Inc.
10.57
-3.82%
TRDA Entrada Therapeutics, Inc.
12.43
-3.57%
PHVS Pharvaris N.V.
21.25
-0.19%
PTGX Protagonist Therapeutics, Inc.
25.70
-4.28%
REPL Replimune Group, Inc.
6.33
-1.40%
MLTX MoonLake Immunotherapeutics
42.43
-1.90%